Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

<p>Supplementary Figure 3</p>

Saved in:

Bibliographic Details
Main Author:	Francisco Exposito (16721403) (author)
Other Authors:	Miriam Redrado (16721406) (author), Maeva Houry (16721409) (author), Katherine Hastings (16721412) (author), Magdalena Molero-Abraham (16721415) (author), Teresa Lozano (16721418) (author), Jose Luis Solorzano (16721421) (author), Julian Sanz-Ortega (16721424) (author), Vera Adradas (16721427) (author), Ramon Amat (16721430) (author), Esther Redin (16721433) (author), Sergio Leon (16721436) (author), Naroa Legarra (16721439) (author), Javier Garcia (16721442) (author), Diego Serrano (16721445) (author), Karmele Valencia (14962695) (author), Camila Robles-Oteiza (16721448) (author), Giorgia Foggetti (15118568) (author), Nerea Otegui (16721451) (author), Enriqueta Felip (16721454) (author), Juan J. Lasarte (16721457) (author), Luis Paz-Ares (16721460) (author), Jon Zugazagoitia (16721463) (author), Katerina Politi (15313362) (author), Luis Montuenga (16721466) (author), Alfonso Calvo (16721469) (author)
Published:	2025
Subjects:	Cancer Cancer Biology Immuno-oncology Immunotherapy Combination immunotherapy Lung Cancer Oncogenes & Tumor Suppressors PD-1
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
by: Francisco Exposito (16721403)
Published: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
by: Francisco Exposito (16721403)
Published: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
by: Francisco Exposito (16721403)
Published: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
by: Francisco Exposito (16721403)
Published: (2025)

Supplementary Figure 1 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Supplementary Figure 2 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Supplementary Figure 3 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Supplementary Figure 4 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Supplementary Table 1 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Table 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Table 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
by: Renumathy Dhanasekaran (14962092)
Published: (2025)

Image 1_Circulating PD-1+ effector memory T cells predict anti-PD-1 efficacy in advanced gastric cancer.tif
by: Kongcheng Wang (6108695)
Published: (2025)

Image 2_Circulating PD-1+ effector memory T cells predict anti-PD-1 efficacy in advanced gastric cancer.tif
by: Kongcheng Wang (6108695)
Published: (2025)